Abstract
Renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are commonly used in the management of hypertension. High blood pressure is a vital risk factor for cardiovascular disease. This study aims to establish any significant difference in using ACEIs and ARBs in managing hypertension. We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to conduct this systematic review. We searched PubMed, MEDLINE, and ScienceDirect for articles published in the last 20 years (2003 to 2023). Our search was last done on the 27th of June, 2023. Following the initial search, 8,313 articles were found on PubMed. After screening the articles selected from the databases, 10 articles examining 1,621,445 patients were selected for the final study. Three articles were identified that compared ACEI and ARB in their capacity to lower blood pressure. Six articles compared both medications' capacity to reduce cardiovascular events and mortality. Five articles were identified that compared both classes of drugs for adverse effects. This study was made to determine whether or not there is a difference between the use of ACEIs and ARBs in the treatment of hypertension. The study showed that both ACEIs and ARBs are similar in their efficacy in lowering blood pressure. However, ACEI was revealed to be superior to ARB in reducing cardiovascular events and all-cause mortality. ARB was shown to be better tolerated by patients than ACEI.
Keywords: angiotensin-converting enzyme inhibitors, lisinopril, enalapril, benazepril, candesartan, irbesartan, losartan, angiotensin receptor blockers, high blood pressure, hypertension
Introduction and background
Introduction
"An estimated 1.28 billion adults aged 30-79 years worldwide have hypertension, most (two-thirds) living in low- and middle-income countries"-World Health Organization [1]. Renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), are widely used in the management of hypertension [2-5]. While both ACEIs and ARBs effectively control blood pressure, they exert their effects at different sites. ACEIs inhibit the conversion of angiotensin-1 to the active angiotensin-2, whereas ARBs competitively bind to angiotensin-2 receptors, thereby inactivating it [6-8]. High blood pressure is a vital risk factor for cardiovascular disease [9,10]. Although both classes of antihypertensives are used for managing hypertension, only a few studies have compared both classes of medications for safety and efficacy in lowering blood pressure and preventing cardiovascular outcomes [11-14]. This study aims to establish any significant difference in using ACEIs and ARBs in managing hypertension [15-20]. This would help clinicians better decide which class of antihypertensive is superior in controlling high blood pressure and preventing mortality from adverse cardiovascular events and other related causes [21-24].
Method
We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to conduct this systematic review [25].
Inclusion Criteria
Only systematic review articles were included in this study. Only studies published in English and within the last 20 years (2003 to 2023) were included in our study. We only included human studies. We only included studies on adult populations (18 years and above). We included studies that compared ACEIs against ARBs. In this paper, we included one study that examined the efficacy of ACEs against placebo and another that examined ARBs against placebo.
Exclusion Criteria
We excluded articles that combined ACEIs and ARBs as a joint group of medication (RAAS inhibitors) compared to other antihypertensives. Studies about children (below 18 years of age) were excluded. Animal studies were excluded.
Data Sources
We searched PubMed, MEDLINE, and ScienceDirect for articles published in the last 20 years (2003 to 2023). Our search was done between May and June, 2023. The date of our last search is the 27th of June, 2023. This is represented in Table 1.
Table 1. Databases used in this article.
Mesh: Medical Subject Headings
| Database | Search strategy | Papers identified |
| PubMed/MEDLINE | MeSH | 8,313 |
| PubMed | Regular keyword | 282 |
| ScienceDirect | Regular keyword | 3,239 (2021-2023) |
Search Strategy
Using Boolean "AND" and "OR", we combined the following keywords: hypertension, high blood pressure, angiotensin-converting enzyme inhibitor, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, angiotensin receptor blockers, losartan, valsartan, irbesartan, and candesartan. We used the Medical Subject Headings (MeSH) search strategy to generate the following keywords and combined them in our search of PubMed/MEDLINE. The search was restricted to MeSH, drug therapy, therapy, toxicity, therapeutic use, and adverse effects. This is shown in Table 2.
Table 2. Search strategy used in this article.
| Database: PubMed/MEDLINE Date: 27/06/2023 | Search words | Number of entries |
| #1 | Hypertension OR high blood pressure OR ( "hypertension/drug therapy"[Majr] OR "hypertension/therapy"[Majr] ) | 757,333 |
| #2 | Angiotensin receptor blockers OR losartan OR valsartan OR irbesartan OR candesartan OR ( "angiotensin receptor antagonists/adverse effects"[Majr] OR "angiotensin receptor antagonists/therapeutic use"[Majr] OR "angiotensin receptor antagonists/toxicity"[Majr] ) | 45,410 |
| #3 | Angiotensin-converting enzyme inhibitors OR benazepril OR captopril OR enalapril OR fosinopril OR lisinopril OR moexipril OR perindopril OR quinapril OR ramipril OR trandolapril OR ( "angiotensin-converting enzyme inhibitors/adverse effects"[Majr] OR "angiotensin-converting enzyme inhibitors/therapeutic use"[Majr] OR "angiotensin-converting enzyme inhibitors/toxicity"[Majr] ) | 64,451 |
| #4 | #1 AND #2 AND #3 | 8,313 |
Screening
Two authors searched the databases independently to select articles that met the inclusion and exclusion criteria. Where there were disagreements, a third author was included to resolve this. We checked the titles of the articles and the abstract to select articles that would fit the goal of this study. Twenty-five articles were selected after screening.
Risk of Bias
Two authors were involved in the appraisal of the selected articles for quality. Both authors agreed upon 10 articles that met this study's goal. The assessment of multiple systematic reviews (AMSTAR) checklist for systematic reviews was used, and only medium- and high-quality studies were included [26]. Quality assessment is summarized in Table 3:
Table 3. Summary of risk of bias and quality assessment .
AMSTAR: assessment of multiple systematic reviews; PICO: population, intervention, comparators, outcomes; RoB: risk of bias; RCTs: randomized controlled trials
| AMSTAR | Li et al. (2014) [2] | Salvador et al. (2017) [6] | Xie et al. (2018) [9] | Powers et al. (2012) [11] | Matchar et al. (2008) [12] | Wang et al. (2018) [27] | lv et al. (2018) [28] | Chaugai et al. (2016) [29] | Heran et al. (2008) [30] | Heran et al. (2008) [31] |
| Did the research questions and inclusion criteria for the review include the components of PICO? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the report of the review contain an explicit statement that the review methods were established prior to the conduct of the review, and did the report justify any significant deviations from the protocol? | YES | NO | YES | YES | YES | NO | YES | NO | YES | YES |
| Did the review authors explain their selection of the study designs for inclusion in the review? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the review authors use a comprehensive literature search strategy? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the review authors perform study selection in duplicate? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the review authors perform data extraction in duplicate? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the review authors provide a list of excluded studies and justify the exclusions? | YES | NO | NO | NO | NO | NO | YES | NO | YES | YES |
| Did the review authors describe the included studies in adequate detail? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the review authors use a satisfactory technique for assessing the risk of bias (RoB) in individual studies that were included in the review? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the review authors report on the sources of funding for the studies included in the review? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| If meta-analysis was performed, did the review authors use appropriate methods for statistical combination of results? RCTs | UNCLEAR | YES | YES | YES | YES | UNCLEAR | YES | YES | UNCLEAR | UNCLEAR |
| If meta-analysis was performed, did the review authors assess the potential impact of RoB in individual studies on the results of the meta-analysis or other evidence synthesis? | UNCLEAR | YES | YES | YES | YES | UNCLEAR | YES | YES | UNCLEAR | UNCLEAR |
| Did the review authors account for RoB in individual studies when interpreting/ discussing the results of the review? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| Did the review authors provide a satisfactory explanation for, and discussion of, any heterogeneity observed in the results of the review? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
| If they performed quantitative synthesis, did the review authors carry out an adequate investigation of publication bias (small study bias) and discuss its likely impact on the results of the review? | YES | YES | YES | YES | NO | YES | YES | YES | YES | YES |
| Did the review authors report any potential sources of conflict of interest, including any funding they received for conducting the review? | YES | YES | YES | YES | YES | YES | YES | YES | YES | YES |
Risk of Bias Across Studies
We only selected free articles, while those requiring payment for full access were not selected, even though some met our inclusion criteria. Only systematic reviews and systematic reviews/meta-analyses were included in our study.
Results
After the initial search, 8,313 articles were found on PubMed, and 1,892 duplicates were found and removed. A total of 196 articles were left after applying some inclusion and exclusion criteria in the search. After thoroughly applying the criteria for inclusion, only 25 articles were selected. These articles were assessed for quality, after which 10 articles examining a combined total of 1,621,445 patients were selected for the final study. Three articles were identified that compared ACEI and ARB in their capacity to lower blood pressure. Six articles compared both medications' capacity to reduce cardiovascular events and mortality. Five articles were identified that compared both classes of drugs for adverse effects. The search and screening is represented in Figure 1.
Figure 1. Flow diagram of search strategy and article selection.
Review
Discussion
This study aims to compare the safety and efficacy of ACEIs and ARBs in managing hypertension.
Efficacy in Blood Pressure Control
In a systematic review by Powers et al. carried out in 2012 that compared the effectiveness of ACEI, ARB, and direct renin inhibitors (DRIs) on the management of essential hypertension, 33,611 patients were evaluated for blood pressure [11]. The study was an update on a systematic review initially done in 2007. According to the study, there was no statistical difference in blood pressure control when using either ARBs or ACEIs. When either an ACEI was used alone in therapy or an ARB was used alone, no significant difference was found in their efficacy in reducing blood pressure [11]. Another systematic review conducted by Li et al. in 2014 that compared ARBs to ACEIs in managing hypertension sampled 11,007 patients who were followed up for at least one year [2]. Matchar et al. (2008) also conducted a systematic review that compared ACEI and ARB in managing hypertension. The study sampled 13,532 participants for blood pressure and was of good quality [12]. All three studies showed no clinical significance in the difference between the use of ACEIs and ARBs in managing essential hypertension [2,11,12]. This is summarized in Table 4.
Table 4. ACEI vs ARB in reducing blood pressure.
ACEI: Angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker
| Author and year of publication | Intervention/drug of study | Number of patients | Type of study | Result/conclusion |
| Li et al. (2014) [2] | Blood pressure/(ACEI vs ARB) | 11,007 | Systematic review | There is no significant difference between ACEI and ARB in managing hypertension |
| Powers et al. (2012) [11] | Blood pressure/(ACEI vs ARB) | 798,810 (33,611 for blood pressure) | Systematic review | There is no statistical difference between ACEI and ARB |
| Matchar et al. (2008) [12] | Blood pressure/(ACEI vs ARB) | 345,594 (13,532 for blood pressure) | Systematic review | There is no significant difference between ACEI and ARB in managing hypertension |
Mortality and Cardiovascular Outcomes
In a systematic review and meta-analysis comparing ACEIs and ARBs in the reduction of mortality sampling 73,761 participants conducted by Salvador et al. in 2017, ACEIs were shown to have higher efficacy in reducing mortality due to cardiovascular events and all-cause mortality when compared to ARBs [6]. In a systematic review and meta-analysis by Xie et al. in 2018 that studied the effects of antihypertensives and secondary prevention of cardiovascular diseases, 143,095 participants were examined [9]. It was revealed that while ACEIs were more effective in reducing all-cause mortality and cardiovascular events, ARBs were shown to reduce the risk of combined events. A systematic review by Powers et al., conducted in 2012, compared the efficacy of ACEI, ARB, and DRI in managing essential hypertension [11]. The study included 798,810 participants who were examined for different outcomes. Study participants had at least 12 weeks of follow-up. The study did not show significant differences between the efficacy of ACEIs and ARBs. Wang et al. published a systematic review and meta-analysis in 2018 examining the effects of ACEIs and ARBs on all-cause mortality and renal outcomes for diabetic patients with albuminuria [27]. The study participants were 10,378, and the outcome showed no reduction in all-cause mortality or cardiovascular events in patients treated with ACEIs and ARBs [27]. However, in a systematic review by lv et al. published in 2018, ACEIs were compared to ARBs in hypertensive patients with type 2 diabetes [28]. The study sampled 47,008 participants and revealed a significant reduction in all-cause mortality and major cardiovascular events by ACEIs. In contrast, ARBs failed to reduce all-cause mortality and did not reduce mortality due to cardiovascular events [28]. Chaugai et al. published a systematic review and meta-analysis in 2016 that compared the effects of RAS blockade in preventing atrial fibrillation [29]. The study examined 165,387 patients and showed a significant reduction in the onset and recurrence of atrial fibrillation but did not show any significant difference in the superiority of one class of the drug over another [29]. Overall, ACEIs appear to have higher efficacy in reducing all-cause mortality and mortality and morbidity due to cardiovascular events when compared to ARBs, as the studies that support this statement are more recent and have a significant number of study participants [6,9,28]. Although one of the studies that reported no significant difference in mortality and cardiovascular outcome between ARBs and ACEIs appears to have a very high number of participants (798,810), not all were assessed for the same outcome. The follow-up period appears short compared to other studies [11]. This is represented in Table 5.
Table 5. : Summary of ACEI vs ARB in outcomes of mortality and cardiovascular events.
ARB: Angiotensin receptor blocker; ACEI: angiotensin-converting enzyme inhibitor; DRI: direct renin inhibitor
| Author and year of publication | Intervention/drug of study | Number of patients | Type of study | Result/conclusion |
| Salvador et al. (2017) [6] | Cardiovascular events, mortality (ACEI vs ARB) | 73,761 | Systematic review and meta-analysis | ACEI was shown to have higher efficacy in the reduction of cardiovascular events and all-cause mortality than ARB |
| Chaugai et al. (2016) [29] | Atrial fibrillation (ACEI vs ARB) | 165,387 | Systematic review and meta-analysis | Both ACEI and ARB showed similar efficacy in the reduction of atrial fibrillation |
| Xie et al. (2018) [9] | Cardiovascular events, mortality (blood pressure lowering drugs) | 143,095 | Systematic review and meta-analysis | ACEI was shown to reduce all-cause mortality and cardiovascular events, whereas ARB reduced the risk of combined events |
| Powers et al. (2012) [11] | Cardiovascular events, mortality (ACEI, ARB, and DRI) | 798,810 | Systematic review | No significant difference was found in efficacy between ACEI and ARB |
| Wang et al. (2018) [27] | Cardiovascular event, mortality (ACEI vs ARB in people with diabetes with albuminuria) | 10378 | Systematic review and meta-analysis | No reduction in all-cause mortality or cardiovascular events for either ACEI or ARB |
| lv et al. (2018) [28] | Cardiovascular event, mortality (ACEI vs ARB in patients with type 2 diabetes) | 47,008 | Systematic review and meta-analysis | ACEI showed a significant reduction in all-cause mortality and major cardiovascular events, whereas ARB did not |
Adverse Effects
A systematic review by Li et al. in 2014 compared ARBs to ACEIs in managing hypertension [2]. The study involved 11,007 patients with a follow-up period of at least one year. The study indicates that patients were slightly more likely to tolerate ARBs better than ACEIs. Patients taking ACEIs had a slightly higher chance of developing dry cough than ARBs, as established in the systematic review by Powers et al. in 2012 [11]. Angioedema has also been found to be more associated with ACEIs than ARBs. Heran et al. (2008) published a systematic review examining ARBs' efficacy in managing hypertension [30]. The study had 13,451 participants and revealed that when compared with placebo, ARBs were shown to reduce withdrawal due to adverse effects [30]. There was no change in withdrawal due to adverse effects when ACEIs were compared to placebo in a different systematic review by Heran et al. published in 2008 that reviewed the efficacy of ACEIs in lowering blood pressure in 12,954 participants [31]. Matcher et al. (2008) showed no significant difference in adverse effects when ACEIs and ARBs were compared when the rate of cough was excluded [12]. Overall, ARBs are better tolerated than ACEIs, likely due to the increased rate of dry cough associated with ACEIs [12]. This is summarized in Table 6.
Table 6. Summary of ACEI vs ARB in producing adverse reactions.
ARB: Angiotensin receptor blocker; ACEI: angiotensin-converting enzyme inhibitor; DRI: direct renin inhibitor
| Author and year of publication | Intervention/drug of study | Number of patients | Type of study | Result/conclusion |
| Li et al. (2014) [2] | Adverse effects/(ACEI, ARB) | 11,007 | Systematic review | ARB is slightly better tolerated than ACEI |
| Powers et al. (2012) [11] | Adverse effects (ACEI, ARB, DRI) | 798,810 | Systematic review | ACEI has a stronger association with dry cough and angioedema than ARB |
| Matcher et al. (2008) [12] | Adverse effects (ACEI, ARB) | 345,594 | Systematic review | There was no significant difference in adverse effects between ACEI and ARB. However, there is a slight increase in the tolerability of ARB when compared to ACEI |
| Heran et al. (2008) [30] | Adverse effects (ARB) | 13,451 | Systematic review | Reduced withdrawal due to adverse effects when compared with placebo |
| Heran et al. (2008) [31] | Adverse effects (ACEI) | 12,954 | Systematic review | No change in withdrawal due to adverse effects when compared with placebo |
Limitations of the Study
Our study has several limitations. Firstly, only studies published in English were selected for this study. Our study only examined systematic reviews and did not select other research articles. We excluded studies that included children. Only human studies were included. Some articles that met our inclusion and exclusion criteria were excluded from this study because there was no free access to the said articles.
Conclusions
This study was made to determine whether or not there is a difference between the use of ACEIs and ARBs in the treatment of hypertension. The study showed that both ACEIs and ARBs are similar in their efficacy in lowering blood pressure. However, ACEIs were shown to reduce all-cause mortality and mortality due to cardiovascular events. In contrast, ARBs have not demonstrated a similar outcome to ACEIs. More patients using AACEIs withdraw from the medication due to adverse effects than patients prescribed with ARBs.
The authors have declared that no competing interests exist.
Author Contributions
Concept and design: Tariladei S. Peresuodei, Abhishek Gill, Chijioke Orji, Maiss Reghefaoui , Michell Susan Saavedra Palacios, Tuheen Sankar Nath
Acquisition, analysis, or interpretation of data: Tariladei S. Peresuodei, Abhishek Gill, Chijioke Orji, Maiss Reghefaoui , Michell Susan Saavedra Palacios, Tuheen Sankar Nath
Drafting of the manuscript: Tariladei S. Peresuodei
Critical review of the manuscript for important intellectual content: Tariladei S. Peresuodei, Abhishek Gill, Chijioke Orji, Maiss Reghefaoui , Michell Susan Saavedra Palacios, Tuheen Sankar Nath
Supervision: Tariladei S. Peresuodei, Abhishek Gill, Chijioke Orji, Maiss Reghefaoui , Michell Susan Saavedra Palacios, Tuheen Sankar Nath
References
- 1.Hypertension. [ Mar; 2023 ]. 2023. https://www.who.int/news-room/fact-sheets/detail/hypertension https://www.who.int/news-room/fact-sheets/detail/hypertension
- 2.Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Li EC, Heran BS, Wright JM. Cochrane Database Syst Rev. 2014:0. doi: 10.1002/14651858.CD009096.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Valsartan: long-term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension. Bremner AD, Baur M, Oddou-Stock P, Bodin F. Clin Exp Hypertens. 1997;19:1263–1285. doi: 10.3109/10641969709083217. [DOI] [PubMed] [Google Scholar]
- 4.24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Fogari R, Ambrosoli S, Corradi L, et al. J Hypertens. 1997;15:1511–1518. doi: 10.1097/00004872-199715120-00020. [DOI] [PubMed] [Google Scholar]
- 5.Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Flack JM, Saunders E, Gradman A, et al. Clin Ther. 2001;1922:1193–1208. doi: 10.1016/s0149-2918(01)80101-6. [DOI] [PubMed] [Google Scholar]
- 6.Angiotensin-converting enzyme inhibitors reduce mortality compared to angiotensin receptor blockers: systematic review and meta-analysis. Salvador GL, Marmentini VM, Cosmo WR, Junior EL. Eur J Prev Cardiol. 2017;24:1914–1924. doi: 10.1177/2047487317728766. [DOI] [PubMed] [Google Scholar]
- 7.The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias. Iravanian S, Dudley SC Jr. Heart Rhythm. 2008;5:0–7. doi: 10.1016/j.hrthm.2008.02.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Comparison of the efficacy and tolerability of telmisartan and enalapril in patients of mild to moderate essential hypertension. Akat PB, Bapat TR, Murthy MB, Karande VB, Burute SR. https://pubmed.ncbi.nlm.nih.gov/20871766/#:~:text=Conclusion%3A%20Telmisartan%20produces%20a%20greater,is%20commonly%20encountered%20with%20enalapril. Indian J Pharmacol. 2010;42:153–156. doi: 10.4103/0253-7613.66838. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Blood pressure-lowering drugs and secondary prevention of cardiovascular disease: systematic review and meta-analysis. Xie W, Zheng F, Evangelou E, et al. J Hypertens. 2018;36:1256–1265. doi: 10.1097/HJH.0000000000001720. [DOI] [PubMed] [Google Scholar]
- 10.Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review. Padwal R, Straus SE, McAlister FA. BMJ. 2001;322:977–980. doi: 10.1136/bmj.322.7292.977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Updated report on comparative effectiveness of ACE inhibitors, ARBs, and direct renin inhibitors for patients with essential hypertension: much more data, little new information. Powers BJ, Coeytaux RR, Dolor RJ, et al. J Gen Intern Med. 2012;27:716–729. doi: 10.1007/s11606-011-1938-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Matchar DB, McCrory DC, Orlando LA, et al. Ann Intern Med. 2008;148:16–29. doi: 10.7326/0003-4819-148-1-200801010-00189. [DOI] [PubMed] [Google Scholar]
- 13.Effect of treatment with candesartan or enalapril on subcutaneous small artery structure in hypertensive patients with noninsulin-dependent diabetes mellitus. Rizzoni D, Porteri E, De Ciuceis C, et al. Hypertension. 2005;45:659–665. doi: 10.1161/01.HYP.0000153308.91043.97. [DOI] [PubMed] [Google Scholar]
- 14.Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J. N Engl J Med. 2004;351:1952–1961. doi: 10.1056/NEJMoa042274. [DOI] [PubMed] [Google Scholar]
- 15.Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Lacourcière Y, Bélanger A, Godin C, Hallé JP, Ross S, Wright N, Marion J. Kidney Int. 2000;58:762–769. doi: 10.1046/j.1523-1755.2000.00224.x. [DOI] [PubMed] [Google Scholar]
- 16.Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. Malacco E, Omboni S, Volpe M, Auteri A, Zanchetti A. J Hypertens. 2010;28:2342–2350. doi: 10.1097/HJH.0b013e32833e116b. [DOI] [PubMed] [Google Scholar]
- 17.Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G. Am J Ther. 1999;6:161–166. doi: 10.1097/00045391-199905000-00007. [DOI] [PubMed] [Google Scholar]
- 18.Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Ruilope L, Jäger B, Prichard B. Blood Press. 2001;10:223–229. doi: 10.1080/08037050152669747. [DOI] [PubMed] [Google Scholar]
- 19.A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension. Gradman AH, Arcuri KE, Goldberg AI, Ikeda LS, Nelson EB, Snavely DB, Sweet CS. Hypertension. 1995;25:1345–1350. doi: 10.1161/01.hyp.25.6.1345. [DOI] [PubMed] [Google Scholar]
- 20.Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. Black HR, Graff A, Shute D, et al. J Hum Hypertens. 1997;11:483–489. doi: 10.1038/sj.jhh.1000482. [DOI] [PubMed] [Google Scholar]
- 21.2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) James PA, Oparil S, Carter BL, et al. JAMA. 2014;311:507–520. doi: 10.1001/jama.2013.284427. [DOI] [PubMed] [Google Scholar]
- 22.Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients. Fogari R, Mugellini A, Zoppi A, Lazzari P, Destro M, Rinaldi A, Preti P. J Hum Hypertens. 2006;20:177–185. doi: 10.1038/sj.jhh.1001964. [DOI] [PubMed] [Google Scholar]
- 23.Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group. Karlberg BE, Lins LE, Hermansson K. J Hypertens. 1999;17:293–302. doi: 10.1097/00004872-199917020-00015. [DOI] [PubMed] [Google Scholar]
- 24.Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients. McInnes GT, O'Kane KP, Istad H, Keinänen-Kiukaanniemi S, Van Mierlo HF. J Hum Hypertens. 2000;14:263–269. doi: 10.1038/sj.jhh.1000997. [DOI] [PubMed] [Google Scholar]
- 25.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Page MJ, McKenzie JE, Bossuyt PM, et al. BMJ. 2021;372:0. doi: 10.1186/s13643-021-01626-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. Shea BJ, Reeves BC, Wells G, et al. BMJ. 2017;358:0. doi: 10.1136/bmj.j4008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Wang K, Hu J, Luo T, et al. Kidney Blood Press Res. 2018;43:768–779. doi: 10.1159/000489913. [DOI] [PubMed] [Google Scholar]
- 28.Comparison of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular outcomes in hypertensive patients with type 2 diabetes mellitus: a PRISMA-compliant systematic review and meta-analysis. Lv X, Zhang Y, Niu Y, Song Q, Zhao Q. Medicine (Baltimore) 2018;97:0. doi: 10.1097/MD.0000000000010256. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Effects of RAAS blockers on atrial fibrillation prophylaxis: an updated systematic review and meta-analysis of randomized controlled trials. Chaugai S, Meng WY, Ali Sepehry A. J Cardiovasc Pharmacol Ther. 2016;21:388–404. doi: 10.1177/1074248415619490. [DOI] [PubMed] [Google Scholar]
- 30.Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Heran BS, Wong MM, Heran IK, Wright JM. Cochrane Database Syst Rev. 2008:0. doi: 10.1002/14651858.CD003822.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Heran BS, Wong MM, Heran IK, Wright JM. Cochrane Database Syst Rev. 2008:0. doi: 10.1002/14651858.CD003823.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]